emerg
evid
suggest
dipeptidyl
inhibitor
use
treat
type
diabet
may
nephroprotect
effect
beyond
reduc
renal
risk
confer
glycem
control
ubiquit
protein
exopeptidas
activ
exist
cell
membranebound
solubl
form
global
burden
diabet
escal
alarm
rate
estim
million
peopl
worldwid
afflict
diseas
mostli
type
diabet
furthermor
global
diabet
preval
forecast
increas
million
peopl
microvascular
complic
result
hyperglycemia
includ
kidney
diseas
major
clinic
sequela
type
diabet
consequ
approxim
peopl
type
diabet
also
chronic
kidney
diseas
make
diabet
lead
caus
chronic
kidney
diseas
intens
glycem
control
shown
reduc
risk
kidney
diseas
microvascular
complic
type
diabet
larg
clinic
outcom
studi
uk
prospect
diabet
studi
ukpd
action
control
cardiovascular
risk
diabet
accord
studi
action
diabet
vascular
diseas
preterax
diamicron
modifi
releas
control
evalu
advanc
studi
howev
residu
risk
kidney
complic
remain
substanti
even
current
standard
care
includ
tight
glycem
control
peopl
diabet
three
time
like
die
kidney
diseas
without
diabet
new
treatment
diabet
nephropathi
emerg
sinc
angiotensinreceptor
blocker
irbesartan
losartan
demonstr
efficaci
indic
sinc
sever
novel
pharmacotherapeut
approach
diabet
kidney
diseas
fail
exhibit
benefici
effect
care
control
clinic
trial
consequ
greater
interest
potenti
renoprotect
effect
type
diabet
drug
independ
glucoselow
properti
socal
pleiotrop
effect
recent
member
newest
class
oral
glucoselow
drug
sodiumglucos
inhibitor
appear
slow
progress
diabet
kidney
diseas
exploratori
analys
cardiovascular
outcom
studi
renoprotect
effect
confirm
clinic
trial
design
primarili
evalu
renal
outcom
inhibitor
may
becom
standard
care
diabet
nephropathi
togeth
angiotensinconvert
enzym
inhibitor
angiotensinreceptor
blocker
dipeptidyl
inhibitor
also
one
newer
type
oral
glucoselow
drug
licens
type
diabet
firstinclass
sitagliptin
approv
unit
state
inhibitor
also
known
gliptin
oral
administ
medic
moder
glycem
efficaci
carri
low
risk
hypoglycemia
weight
gain
emerg
evid
suggest
inhibitor
may
also
renoprotect
effect
independ
glucoselow
properti
despit
common
mechan
action
inhibitor
chemic
divers
class
molecul
whose
contrast
structur
result
clinic
import
differ
pharmacolog
amongst
global
market
inhibitor
linagliptin
particular
interest
respect
pleiotrop
renoprotect
effect
drug
excret
predominantli
nonren
pathway
henc
requir
dose
adjust
chronic
kidney
diseas
intrins
extrins
factor
contrast
sitagliptin
saxagliptin
alogliptin
vildagliptin
excret
mainli
kidney
necessit
dose
adjust
renal
impair
patient
safeti
precaut
furthermor
linagliptin
first
far
inhibitor
evalu
random
clinic
trial
design
robustli
assess
renal
outcom
ongo
cardiovascular
renal
microvascular
outcom
studi
linagliptin
patient
type
diabet
mellitu
carmelina
r
review
describ
accumul
bodi
evid
suggest
linagliptin
may
protect
effect
diabet
nephropathi
focu
preclin
studi
put
molecular
mechan
enzym
divers
biolog
also
known
glycoprotein
glycoprotein
serin
exopeptidas
activ
enzym
commiss
number
catalyt
activ
remov
ntermin
dipeptid
peptid
contain
prolin
alanin
second
posit
structur
monomer
type
ii
transmembran
protein
amino
acid
residu
consist
short
intracellular
ntermin
tail
hydrophob
transmembran
segment
extracellular
portion
account
bulk
protein
extracellular
portion
contain
glycosyl
region
cysteinerich
region
catalyt
domain
cterminu
figur
addit
transmembran
form
also
exist
slightli
smaller
solubl
form
residu
lack
intracellular
transmembran
region
membranebound
form
retain
extracellular
portion
includ
catalyt
domain
membranebound
exist
mainli
dimer
although
tetram
two
membranebound
form
two
solubl
form
also
form
membranebound
ubiquit
protein
present
organ
rang
differ
tissu
cell
type
includ
immun
cell
vascular
endotheli
cell
solubl
found
blood
bodi
fluid
thought
aris
shed
membran
form
although
precis
sourc
delin
discov
year
ago
complex
biolog
still
unravel
multifunct
protein
first
character
tcell
differenti
antigen
distinct
enzymat
activ
involv
multipl
proteinprotein
interact
includ
associ
adenosin
deaminas
tissu
hiv
envelop
glycoprotein
lymphocyt
known
proteinprotein
interact
partner
includ
cxc
chemokin
receptor
type
chemokin
receptor
tyrosin
phosphatas
sodiumhydrogen
fibronectin
collagen
growth
factor
ii
receptor
physic
interact
catalyt
activ
liber
plasma
membran
produc
solubl
circul
form
lack
intracellular
tail
transmembran
region
account
substanti
proport
activ
addit
exopeptidas
activ
also
function
bind
protein
bind
fibronectin
adenosin
deaminas
ada
amongst
proteinbind
partner
republish
permiss
permiss
convey
copyright
clearanc
center
inc
involv
divers
biolog
process
immun
system
modul
includ
tcell
costimul
activ
intracellular
signal
transduct
pathway
natriuresi
cellcel
interact
cellular
interact
extracellular
matrix
cellular
entri
virus
hiv
middl
eastern
respiratori
syndrom
coronaviru
enzymat
activ
shown
cleav
wide
varieti
biopeptid
vitro
assay
establish
bona
fide
physiolog
substrat
wellknown
latter
peptid
hormon
glucagonlik
peptid
glp
glucosedepend
insulinotrop
peptid
respons
incretin
effect
ie
amplif
insulin
secret
follow
oral
intraven
glucos
despit
similar
level
blood
glucos
thought
inhibitor
elicit
antihyperglycem
effect
predominantli
prevent
degrad
although
mechan
may
also
involv
confirm
physiolog
substrat
includ
stromal
cellderiv
factor
sdf
peptid
tyrosinetyrosin
pyy
substanc
p
although
present
throughout
bodi
level
vari
wide
differ
organ
tissu
amongst
organ
highest
amount
activ
per
gram
tissu
found
kidney
level
membranebound
protein
plasma
enzymat
activ
alter
sever
pathophysiolog
state
includ
cancer
inflamm
infect
immun
disord
type
diabet
kidney
diseas
increas
level
solubl
type
diabet
seem
least
partli
deriv
proteolyt
process
membranebound
kallikreinrel
peptidas
circul
helper
th
cell
kidney
express
enzymat
activ
demonstr
occur
sever
tissu
type
healthi
organ
diseas
condit
rat
report
present
glomerular
podocyt
proxim
tubul
kidney
notabl
membranebound
form
complex
brush
border
renal
proxim
tubul
appear
modul
na
h
exchang
reduc
natriuresi
separ
exopeptidas
activ
proxim
tubuleloc
enabl
reabsorpt
prolinecontain
oligopeptid
mrna
protein
enzymat
activ
detect
preglomerular
microvascular
smooth
muscl
cell
glomerular
mesangi
cell
spontan
hypertens
normotens
rat
rat
either
fed
highfat
diet
treat
streptozotocin
stz
induc
diabet
overexpress
renal
tubular
cell
interestingli
defici
protect
rat
kidney
acut
ischemiareperfus
injuri
human
express
enzymat
activ
found
present
glomerulu
primarili
podocyt
patholog
renal
condit
healthi
kidney
inflammatori
cytokin
elicit
express
human
glomerular
epitheli
cell
furthermor
exposur
human
glomerular
endotheli
cell
high
glucos
concentr
vitro
increas
mrna
enzymat
activ
contrast
found
present
lumin
side
brush
border
membran
proxim
tubular
cell
healthi
human
kidney
interestingli
urinari
activ
found
significantli
higher
individu
type
diabet
albuminuria
compar
nonalbuminur
diabet
patient
healthi
individu
furthermor
regress
analysi
relationship
stage
chronic
kidney
diseas
serum
level
proteas
found
angiotensinconvert
enzym
activ
significantli
correl
estim
glomerular
filtrat
rate
egfr
case
relationship
invers
patient
highest
angiotensinconvert
enzym
activ
exhibit
lowest
egfr
studi
also
found
correl
increas
activ
diabet
nondiabet
kidney
diseas
base
studi
seem
plausibl
play
patholog
role
diabet
nephropathi
although
revers
causat
rule
consequ
much
interest
effect
inhibitor
linagliptin
diseas
linagliptin
extens
investig
anim
model
diabet
nephropathi
well
nondiabet
kidney
diseas
tabl
mous
model
hypertens
diabet
linagliptin
monotherapi
reduc
glomerulosclerosi
renal
oxid
stress
combin
linagliptin
angiotensinreceptor
blocker
telmisartan
reduc
albuminuria
telmisartan
alon
rat
model
type
diabet
serum
level
elev
linagliptin
reduc
level
advanc
glycat
end
product
age
receptor
rage
well
reduc
albuminuria
lymphocyt
infiltr
glomeruli
deoxyguanosin
level
kidney
marker
renal
oxid
stress
chang
occur
without
alter
blood
glucos
level
followup
studi
found
defici
mimick
effect
suggest
inhibit
respons
reduc
agerag
signal
rather
offtarget
effect
linagliptin
similarli
mous
model
type
diabet
linagliptin
reduc
albuminuria
kidney
damag
without
affect
blood
glucos
level
notabl
studi
conduct
author
colleagu
linagliptin
inhibit
tubulointerstiti
fibrosi
mous
model
diabet
nephropathi
character
extens
fibrosi
stzinduc
diabet
mice
well
reduc
glomerulosclerosi
albuminuria
studi
followon
investig
shed
light
molecular
mechan
renoprotect
effect
linagliptin
research
discuss
intriguingli
separ
studi
found
linagliptin
lower
albuminuria
diabet
mice
receptor
lack
receptor
howev
linagliptin
treatment
normal
kidney
patholog
reduc
renal
oxid
stress
increas
natriuresi
upregul
express
mice
rat
model
earli
diabet
nephropathi
stzinduc
diabet
spraguedawley
rat
treatment
linagliptin
reduc
albuminuria
without
affect
blood
glucos
level
linagliptin
also
attenu
express
vascular
endotheli
growth
factor
vegf
oxid
stress
marker
nadph
oxidas
nox
renoprotect
effect
linagliptin
also
seen
nondiabet
kidney
diseas
rat
model
renal
hypertens
linagliptin
reduc
oxid
stress
provid
addit
renoprotect
effect
howev
rat
obesityrel
nephropathi
linagliptin
reduc
damag
glomerular
filtrat
barrier
zucker
obes
rat
glomerular
endotheli
fenestra
podocyt
effac
slit
pore
diaphragm
proteinuria
reduc
activ
kidney
tissu
increas
plasma
level
furthermor
nephrectomi
rat
model
chronic
kidney
diseas
linagliptin
reduc
albuminuria
kidney
fibrosi
mice
nephrectomi
reduct
tubulointerstiti
fibrosi
glomerulosclerosi
result
linagliptin
treatment
occur
even
anim
indic
renoprotect
effect
independ
signal
anoth
mous
model
linagliptin
reduc
tubulointerstiti
injuri
induc
periton
inject
free
fatti
acidbound
albumin
without
alter
blood
glucos
level
inhibitor
also
demonstr
renoprotect
effect
anim
model
diabet
nephropathi
review
elsewher
evid
suggest
pleiotrop
renoprotect
effect
linagliptin
anim
model
result
number
differ
molecular
mechan
renal
fibrosi
final
common
pathway
progress
kidney
diseas
disrupt
kidney
structur
thu
reduc
organ
filtrat
function
two
main
loci
renal
fibrosi
tubulointerstiti
space
glomerulu
describ
linagliptin
amelior
kidney
fibrosi
tubulointerstiti
fibrosi
glomerulosclerosi
albuminuria
murin
model
type
diabet
without
alter
blood
glucos
level
consist
studi
show
antifibrot
effect
linagliptin
heart
aorta
peritoneum
anim
model
antifibrot
chang
kidney
occur
togeth
inhibit
endothelialtomesenchym
transit
endmt
thought
import
sourc
kidney
fibroblast
play
key
role
renal
fibrosi
sever
differ
process
respons
tissu
accumul
activ
fibroblast
cell
respons
establish
progress
fibrot
process
via
excess
product
collagen
extracellular
matrix
protein
endmt
recent
discov
process
follow
elucid
complex
process
cell
detach
endotheli
layer
lose
specif
molecular
marker
acquir
mesenchym
specif
myofibroblast
phenotyp
myofibroblast
invad
interstiti
space
express
excess
quantiti
protein
muscl
actin
type
collagen
respons
fibrosi
endmt
induc
sever
molecular
pathway
import
initi
transform
growth
abovedescrib
murin
model
type
diabet
studi
author
collabor
immunohistochem
western
blot
analys
reveal
upregul
glomerular
basement
membran
tubul
peritubular
vascular
cell
kidney
diabet
mice
compar
control
mice
howev
linagliptin
reduc
express
enzymat
activ
well
express
separ
experi
studi
linagliptin
inhibit
endmt
cultur
human
dermal
microvascular
endotheli
cell
reduc
phosphoryl
transcript
factor
play
essenti
role
superfamili
signal
furthermor
analysi
microrna
mir
profil
found
b
c
suppress
diabet
kidney
cultur
endotheli
cell
restor
linagliptin
treatment
bind
site
found
utr
use
report
gene
construct
shown
suppress
gene
express
find
confirm
separ
studi
differ
anim
model
chronic
kidney
diseas
nephrectomi
rat
linagliptin
treatment
restor
level
suppress
induct
profibrot
mir
discov
approxim
year
ago
mir
class
small
approxim
nt
noncod
rna
molecul
bind
mrna
utr
silenc
gene
express
number
mir
dysregul
kidney
fibrosi
patholog
diabet
nephropathi
includ
famili
gener
suppress
fibrosi
kidney
organ
thu
regard
signatur
mir
fibrot
diseas
target
gene
includ
encod
protein
extracellular
matrix
collagen
laminin
elastin
integrin
therefor
healthi
tissu
appear
suppress
develop
extracellular
matrix
also
target
inflammatori
cytokin
particip
tissu
fibrosi
suppress
express
fibroblast
growth
factor
receptor
subsequ
well
profibrot
signal
shown
downregul
similar
famili
also
antifibrot
effect
kidney
diabet
mice
bidirect
crosstalk
model
diabet
nephropathi
figur
use
stzinduc
murin
model
type
diabet
author
colleagu
subsequ
identifi
new
profibrot
molecular
mechan
compris
interact
integrin
endotheli
cell
interact
modul
signal
induc
endmt
integrin
transmembran
receptor
protein
play
essenti
role
cellular
interact
extracellular
matrix
bind
matrix
protein
well
cell
surfac
receptor
structur
integrin
subunit
compris
extracellular
domain
involv
bind
interact
transmembran
portion
short
cytoplasm
tail
transduc
extracellularintracellular
signal
quaternari
structur
integrin
compris
differ
heterodim
form
subunit
integrin
divers
involv
physiolog
patholog
process
play
critic
role
renal
fibrosi
mediat
signal
membranebound
critic
phosphoryl
residu
integrin
play
key
role
bind
extracellular
matrix
crucial
recent
studi
identifi
interact
integrin
induc
endmt
also
show
interact
disrupt
linagliptin
studi
level
endotheli
integrin
http
peptidas
inhibit
pintegrin
receptor
higher
diabet
fibrot
kidney
control
murin
kidney
howev
treatment
linagliptin
reduc
renal
fibrosi
plasma
cystatin
c
level
suppress
endotheli
level
integrin
pintegrin
receptor
diabet
kidney
cultur
human
dermal
microvascular
endotheli
cell
physic
interact
integrin
increas
high
glucos
concentr
knockdown
rnai
result
suppress
integrin
convers
also
true
furthermor
rnaimedi
knockdown
either
integrin
also
abolish
receptor
heterodim
format
phosphoryl
endmt
interact
integrin
endotheli
cell
also
downregul
express
vegf
receptor
upregul
express
would
expect
tip
balanc
vegf
signal
toward
endmt
stimul
endmt
inhibit
fibrot
process
taken
togeth
studi
suggest
follow
pathophysiolog
role
renal
endotheli
cell
figur
translat
suppress
level
bind
utr
normoglycemia
lost
level
decreas
hyperglycem
condit
subsequ
newli
abund
membranebound
form
complex
integrin
also
translat
suppress
normal
condit
result
phosphoryl
activ
latter
activ
complex
enhanc
heterodim
format
receptor
consequ
bind
parallel
complex
stimul
express
effect
lead
profibrot
endmt
process
importantli
linagliptin
inhibit
process
although
known
interact
membranebound
integrin
result
phosphoryl
latter
due
enzymat
activ
physic
interact
plausibl
antifibrot
effect
observ
recent
studi
via
inhibit
interact
class
effect
specif
linagliptin
note
accompani
commentari
reason
antifibrot
renoprotect
properti
linagliptin
may
share
inhibitor
discuss
later
articl
linagliptin
also
shown
reduc
signal
human
kidney
proxim
tubular
epitheli
cell
high
glucos
concentr
differ
mechan
cationindepend
mannos
receptor
activ
cell
expos
high
glucos
condit
linagliptin
inhibit
activ
cell
line
effect
due
disrupt
proteinprotein
interact
unclear
linagliptin
disrupt
physic
interact
given
differ
chemic
structur
amongst
inhibitor
possibl
even
plausibl
class
effect
mulat
interact
integrin
result
phosphoryl
complex
induc
complex
format
type
type
ii
receptor
enabl
proendmt
signal
respons
balanc
vegf
receptor
tilt
toward
favor
proendmt
signal
respons
vegfa
c
linagliptin
effect
hyperglycemia
linagliptin
restor
level
inhibit
interact
complex
format
type
type
ii
receptor
impair
blunt
proendmt
signal
despit
presenc
ligand
abund
favor
proangiogen
vegf
signal
respons
transform
growth
receptor
reprint
zeisberg
zeisberg
permiss
intern
societi
nephrolog
light
find
notabl
linagliptin
treatment
significantli
reduc
serum
level
doubleblind
random
placebocontrol
mechanist
studi
nondiabet
hypertens
patient
addit
antifibrot
properti
describ
linagliptin
may
protect
kidney
via
sever
pathway
includ
effect
agerag
signal
oxid
stress
inflamm
endotheli
nitric
oxid
activ
increas
level
substrat
studi
underpin
hypothes
discuss
follow
diabet
associ
increas
level
age
ie
protein
lipid
glycat
nonenzymat
maillard
reaction
consequ
exposur
glucos
saccharid
age
contribut
develop
macroand
microvascular
complic
diabet
includ
chronic
kidney
diseas
crosslink
molecul
extracellular
matrix
basement
membran
bind
rage
receptor
activ
rage
age
trigger
oxid
stress
inflamm
pathogen
process
cultur
human
umbil
vein
endotheli
cell
solubl
shown
increas
oxid
stress
express
rage
seemingli
via
bind
effect
block
linagliptin
also
inhibit
ageinduc
increas
level
describ
linagliptin
also
block
agerag
signal
rat
model
type
diabet
basi
studi
appear
crosstalk
agerag
signal
system
may
repres
novel
therapeut
target
prevent
vascular
complic
type
diabet
linagliptin
antioxid
properti
share
inhibitor
may
reflect
uniqu
chemic
structur
within
inhibitor
class
drug
linagliptin
alon
contain
xanthinebas
scaffold
inhibit
xanthin
oxidas
enzym
purin
metabol
gener
reactiv
oxygen
speci
reduc
renal
oxid
stress
associ
linagliptin
treatment
sever
anim
model
describ
furthermor
murin
model
diabet
linagliptin
treatment
reduc
albuminuria
renal
hypertrophi
glucoseindepend
manner
mice
wildtyp
antioxid
function
mice
linagliptin
also
increas
level
antioxid
enzym
catalas
manganes
superoxid
dismutas
howev
mice
reduc
antioxid
function
result
knockout
glucos
dehydrogenas
linagliptin
neither
increas
antioxid
enzym
decreas
albuminuria
kidney
hypertrophi
find
suggest
renoprotect
effect
linagliptin
model
elicit
mainli
via
antioxid
properti
antioxid
effect
linagliptin
might
also
block
posit
feedback
gener
reactiv
oxygen
speci
agerag
signal
diabet
nephropathi
endothelium
play
import
role
maintain
vascular
homeostasi
impair
nitric
oxidemedi
vasodil
endotheli
dysfunct
close
associ
develop
diabet
nephropathi
vivo
model
septic
shock
linagliptin
amelior
vascular
dysfunct
well
reduc
oxid
stress
inflamm
furthermor
vitro
linagliptin
potent
gliptin
test
inhibit
oxid
burst
isol
activ
human
neutrophil
adhes
endotheli
cell
also
potent
direct
vasodil
isol
aortic
ring
subsequ
studi
compris
ex
vivo
vitro
experi
linagliptin
shown
directli
interact
nitric
oxid
synthas
eno
complex
rescu
eno
activ
effect
independ
glucoselow
receptor
signal
furthermor
linagliptin
sitagliptin
vildagliptin
amelior
endotheli
dysfunct
induc
high
glucos
concentr
vitro
chemokin
promot
endotheli
repair
mobil
endotheli
progenitor
cell
bone
marrow
shown
mediat
repair
cell
tissu
ischem
kidney
injuri
describ
earlier
physiolog
substrat
previous
describ
studi
akita
diabet
mice
linagliptin
upregul
express
distal
tubul
kidney
togeth
amelior
kidney
patholog
reduc
renal
oxid
stress
linagliptin
also
increas
renal
express
plasma
level
rat
obesityrel
nephropathi
concomit
reduct
renal
activ
damag
glomerular
filtrat
barrier
proteinuria
relat
interest
linagliptin
reduc
infarct
size
rat
model
cardiac
ischemiareperfus
injuri
effect
associ
significantli
increas
number
cell
posit
receptor
near
within
infarct
area
importantli
linagliptin
shown
elev
plasma
type
diabet
patient
without
chronic
kidney
diseas
random
crossov
placebocontrol
trial
elev
effect
also
seen
small
clinic
studi
sitagliptin
abbrevi
k
equilibrium
dissoci
constant
k
rate
constant
associ
complex
k
rate
constant
dissoci
complex
v
volum
distribut
receptor
express
mani
nonpancreat
tissu
includ
kidney
howev
exact
local
within
organ
yet
robustli
character
due
insuffici
sensit
specif
commerci
avail
antisera
physiolog
role
within
kidney
also
incomplet
understood
appear
encompass
natriuret
effect
mediat
inhibit
proxim
tubul
interestingli
appear
modul
activ
manner
renal
effect
receptor
agonist
review
elsewher
detail
descript
beyond
scope
review
describ
mani
put
renoprotect
effect
linagliptin
seen
anim
indic
receptor
signal
alon
unlik
account
renoprotect
effect
inhibitor
licens
inhibitor
oral
administ
small
molecul
inhibit
plasma
activ
consequ
rais
plasma
concentr
two
three
fold
elev
thu
insulinotrop
effect
thought
primari
mechan
inhibitor
elicit
glucoselow
effect
member
drug
class
appear
approxim
equival
term
antihyperglycem
clinic
efficaci
howev
despit
share
common
mechan
action
inhibitor
compris
chemic
heterogen
class
molecul
import
differ
pharmacokinet
tabl
notabl
linagliptin
one
five
global
market
inhibitor
excret
bodi
mainli
nonren
pathway
consequ
high
level
protein
bind
thu
low
concentr
free
drug
contrast
other
sitagliptin
vildagliptin
saxagliptin
alogliptin
predominantli
remov
via
kidney
necessit
dose
reduct
patient
kidney
diseas
demonstr
headtohead
preclin
studi
compar
linagliptin
sitagliptin
alogliptin
rat
model
chronic
kidney
diseas
studi
linagliptin
inhibitor
whose
exposur
increas
renal
impair
elev
marker
tubular
glomerular
injuri
furthermor
linagliptin
normal
express
follow
key
molecular
marker
urem
cardiomyopathi
model
tissu
inhibitor
matrix
procollagen
type
similarli
separ
studi
util
rat
model
urem
cardiomyopathi
linagliptin
prevent
develop
cardiac
diastol
dysfunct
without
affect
renal
function
theoret
inhibitor
excret
urin
may
modifi
proteolyt
activ
apic
membranebound
proxim
tubul
anoth
intraclass
differ
pharmacokinet
consequ
renoprotect
larg
volum
distribut
linagliptin
compar
inhibitor
indic
greater
tissu
penetr
former
fact
abil
linagliptin
penetr
deep
kidney
tissu
demonstr
vivo
studi
tissu
distribut
linagliptin
wildtyp
rat
use
wholebodi
autoradiographi
measur
tissu
radioact
follow
administr
radiolabel
compound
highest
drug
concentr
locat
kidney
liver
followup
studi
employ
highresolut
autoradiographi
found
linagliptin
kidney
locat
mainli
glomerular
podocyt
brush
border
microvilli
proxim
tubul
similar
distribut
pattern
data
suggest
linagliptin
abl
reach
compart
kidney
vitro
potenc
enzymebind
kinet
also
differ
inhibitor
tabl
ic
approxim
nmoll
linagliptin
potent
inhibitor
addit
compar
analysi
bind
kinet
five
global
market
inhibitor
found
linagliptin
highest
bind
affin
k
nmoll
one
fastest
bind
rate
k
slowest
dissoci
rate
k
pharmacolog
differ
suggest
inhibitor
may
necessarili
vivo
pleiotrop
effect
linagliptin
sever
studi
explor
possibl
ex
vivo
studi
zucker
diabet
fatti
zdf
rat
linagliptin
confer
greater
vascular
protect
sitagliptin
despit
similar
effect
blood
glucos
level
studi
zdf
rat
administ
linagliptin
sitagliptin
placebo
week
first
last
treatment
reduct
blood
glucos
plasma
activ
increas
plasma
insulin
equival
linagliptin
sitagliptin
howev
acetylcholineinduc
vascular
relax
isol
arteri
greater
linagliptin
sitagliptin
inhibit
membranebound
activ
lipid
peroxid
lower
vitro
studi
linagliptin
sitagliptin
suppress
enzymat
activ
protein
level
cultur
human
dermal
microvascular
endotheli
cell
furthermor
linagliptin
sitagliptin
inhibit
endmt
restor
chang
vegfr
level
suppress
increas
integrin
level
decreas
dimer
compar
ex
vivo
studi
linagliptin
elicit
sustain
inhibit
situ
activ
sitagliptin
proxim
tubul
glomerulu
normal
male
wistar
rat
administ
singl
oral
dose
drug
furthermor
linagliptin
sitagliptin
vildagliptin
inhibit
renal
activ
rat
model
renal
ischemiareperfus
injuri
albeit
correl
amelior
histopatholog
assess
tubular
damag
despit
mani
studi
describ
show
renoprotect
effect
linagliptin
inhibitor
anim
model
diabet
nephropathi
nondiabet
kidney
diseas
yet
littl
clinic
data
support
hypothesi
drug
pleiotrop
renal
benefit
although
may
simpli
reflect
pauciti
clinic
studi
design
specif
evalu
renal
outcom
inhibitor
relev
find
report
post
hoc
analysi
savortimi
cardiovascular
safeti
studi
found
clinic
meaning
reduct
albuminuria
saxagliptin
treatment
concomit
improv
either
egfr
hard
renal
outcom
initi
dialysi
renal
transplant
albuminurialow
effect
saxagliptin
associ
effect
glycem
control
similar
teco
studi
sitagliptin
clinic
meaning
chang
albuminuria
studi
design
investig
renoprotect
effect
neither
leader
cardiovascular
safeti
studi
receptor
agonist
liraglutid
appear
improv
renal
outcom
measur
use
composit
end
point
compris
newonset
persist
macroalbuminuria
persist
doubl
serum
creatinin
level
endstag
renal
diseas
death
due
kidney
diseas
hazard
ratio
ci
howev
reduc
risk
advers
renal
outcom
measur
composit
end
point
driven
mainli
soft
outcom
reduc
incid
macroalbuminuria
differ
effect
receptor
agonist
compar
two
inhibitor
would
consist
renal
effect
three
drug
exert
via
liraglutid
elicit
pharmacolog
level
signal
saxagliptin
sitagliptin
elev
high
physiolog
level
random
doubleblind
placebocontrol
clinic
trial
patient
type
diabet
treatment
sitagliptin
affect
renal
hemodynam
interestingli
howev
prospect
cohort
studi
found
treatment
inhibitor
associ
reduc
risk
acut
kidney
injuri
patient
diabet
inhibitor
linagliptin
demonstr
glucoselow
efficaci
toler
type
diabet
patient
kidney
diseas
linagliptin
also
demonstr
efficaci
toler
type
diabet
patient
hypertens
microalbuminuria
interestingli
pool
analysi
four
random
placebocontrol
clinic
trial
design
evalu
glycem
efficaci
found
linagliptin
treatment
associ
signific
reduct
urinari
albumintocreatinin
ratio
uacr
individu
albuminuria
uacr
mgg
alreadi
receiv
standard
care
diabet
nephropathi
angiotensinreceptor
blocker
angiotensinconvert
enzym
inhibitor
furthermor
pool
analysi
random
placebocontrol
clinic
trial
reveal
signific
mean
reduct
advers
renal
event
patient
receiv
linagliptin
howev
underli
studi
design
evalu
renal
outcom
find
hypothesi
gener
fact
subsequ
tm
clinic
trial
design
investig
potenti
albuminurialow
effect
patient
earli
type
diabet
linagliptin
elicit
nonsignific
reduct
uacr
nevertheless
describ
renoprotect
effect
inhibitor
may
predominantli
mediat
antifibrot
action
would
necessarili
manifest
chang
albuminuria
shortterm
patient
earli
type
diabet
mechanist
parallelgroup
random
clinic
studi
patient
earli
type
diabet
suggest
week
treatment
linagliptin
prevent
impair
renal
endotheli
function
measur
chang
basal
renal
endotheli
nitric
oxid
activ
glomerular
hyperfiltr
character
earli
diabet
nephropathi
associ
increas
basal
nitric
oxid
activ
anoth
mechanist
random
clinic
studi
found
week
linagliptin
treatment
improv
microvascular
endotheli
function
compar
placebo
sulphonylurea
glimepirid
crossov
studi
patient
earli
type
diabet
signific
chang
macrovascular
endotheli
function
measur
brachial
flowmedi
vasodil
howev
signific
improv
fast
microvascular
function
measur
chang
blood
flow
dorsal
thenar
site
right
hand
record
laserdoppl
flowmetri
renoprotect
effect
improv
glycem
control
well
establish
linagliptin
inhibitor
therefor
anticip
provid
benefit
via
glucoselow
properti
alon
addit
linagliptin
demonstr
pleiotrop
renoprotect
properti
diabet
nondiabet
anim
model
nephropathi
notabl
antifibrot
effect
mediat
via
interact
mir
integrin
antioxid
properti
linagliptin
also
seem
like
play
potenti
uniqu
renoprotect
role
addit
effect
linagliptin
disrupt
agerag
signal
increas
level
peptid
amelior
endotheli
dysfunct
reduc
inflamm
also
like
import
renoprotect
look
futur
technolog
metabolom
peptidom
simultan
evalu
biomolecul
particular
type
seem
well
suit
identifi
molecular
pathway
lead
renoprotect
inhibitorsgiven
larg
number
biopeptid
potenti
cardioren
effect
whose
physiolog
level
could
affect
inhibit
peptidom
alreadi
demonstr
abil
identifi
global
chang
peptid
level
kidney
plasma
result
linagliptin
treatment
despit
common
mechan
action
inhibitor
compris
heterogen
class
molecul
clinic
relev
differ
pharmacolog
unlik
member
drug
class
linagliptin
nonren
excret
capabl
penetr
variou
compart
kidney
thu
base
pharmacolog
anim
studi
date
linagliptin
appear
offer
greatest
potenti
renoprotect
incretin
therapi
put
renoprotect
properti
linagliptin
yet
demonstr
convincingli
clinic
trial
howev
may
simpli
reflect
scarciti
studi
design
specif
measur
renal
outcom
reason
much
interest
ongo
carmelina
r
studi
larg
eventdriven
placebocontrol
clinic
trial
first
studi
design
adequ
power
robustli
evalu
renal
outcom
treatment
inhibitor
almost
type
diabet
patient
high
cardioren
risk
enrol
carmelina
r
result
anticip
